PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21779389-1 2011 Metformin, an oral insulin-sensitizing drug, is actively transported into cells by organic cation transporters (OCT) 1, 2, and 3 (encoded by SLC22A1, SLC22A2, or SLC22A3), which are tissue specifically expressed at significant levels in various organs such as liver, muscle, and kidney. Metformin 0-9 solute carrier family 22 member 2 Homo sapiens 150-157 22590580-0 2012 Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition. Metformin 107-116 solute carrier family 22 member 2 Homo sapiens 81-85 22590580-1 2012 Genetic polymorphisms of the organic cation transporter 2 (OCT2), encoded by SLC22A2, have been investigated in association with metformin disposition. Metformin 129-138 solute carrier family 22 member 2 Homo sapiens 29-57 22590580-1 2012 Genetic polymorphisms of the organic cation transporter 2 (OCT2), encoded by SLC22A2, have been investigated in association with metformin disposition. Metformin 129-138 solute carrier family 22 member 2 Homo sapiens 59-63 22590580-1 2012 Genetic polymorphisms of the organic cation transporter 2 (OCT2), encoded by SLC22A2, have been investigated in association with metformin disposition. Metformin 129-138 solute carrier family 22 member 2 Homo sapiens 77-84 21677353-8 2011 Although metformin is not metabolized, the latest research has shown that it is actively transported into hepatocytes and renal tubular epithelium, by OCT1 (organic cation transporter 1, encoded by the SLC22A1 gene) and OCT2 (organic cation transporter 2, encoded by the SLC22A2 gene), respectively. Metformin 9-18 solute carrier family 22 member 2 Homo sapiens 220-224 21677353-8 2011 Although metformin is not metabolized, the latest research has shown that it is actively transported into hepatocytes and renal tubular epithelium, by OCT1 (organic cation transporter 1, encoded by the SLC22A1 gene) and OCT2 (organic cation transporter 2, encoded by the SLC22A2 gene), respectively. Metformin 9-18 solute carrier family 22 member 2 Homo sapiens 226-254 21677353-8 2011 Although metformin is not metabolized, the latest research has shown that it is actively transported into hepatocytes and renal tubular epithelium, by OCT1 (organic cation transporter 1, encoded by the SLC22A1 gene) and OCT2 (organic cation transporter 2, encoded by the SLC22A2 gene), respectively. Metformin 9-18 solute carrier family 22 member 2 Homo sapiens 271-278 21779389-6 2011 All tested PPIs significantly inhibited metformin uptake by OCT1, OCT2, and OCT3 in a concentration-dependent manner. Metformin 40-49 solute carrier family 22 member 2 Homo sapiens 66-70 20139901-0 2010 SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Metformin 113-122 solute carrier family 22 member 2 Homo sapiens 0-7 20139901-2 2010 METHODS: The SLC22A2 single nucleotide polymorphism (SNP) 808G/T was genotyped in 400 T2DM patients, including a metformin-treated group (n=200) and a non-metformin-treated group (n=200). Metformin 113-122 solute carrier family 22 member 2 Homo sapiens 13-20 20139901-14 2010 The 808G>T variance in the SLC22A2 gene can affect the plasma lactate level and the incidence of hyperlactacidemia in T2DM patients undergoing metformin therapy. Metformin 146-155 solute carrier family 22 member 2 Homo sapiens 30-37 19251820-10 2009 Moreover, out of a set of 27 compounds p.270Ala>Ser OCT2 was significantly less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2 (e.g., for propranolol: IC(50) wild type versus p.270Ala>Ser 189 versus 895 microM, P < 0.001). Metformin 131-140 solute carrier family 22 member 2 Homo sapiens 52-56 19483665-0 2009 Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Metformin 92-101 solute carrier family 22 member 2 Homo sapiens 35-63 19483665-1 2009 OBJECTIVE: The goal of this study was to determine the effect of a genetic variant in the organic cation transporter 2 (OCT2), OCT2-808G/T, which results in an amino acid change, A270S, on the pharmacokinetics of the antidiabetic drug, metformin. Metformin 236-245 solute carrier family 22 member 2 Homo sapiens 90-118 19483665-1 2009 OBJECTIVE: The goal of this study was to determine the effect of a genetic variant in the organic cation transporter 2 (OCT2), OCT2-808G/T, which results in an amino acid change, A270S, on the pharmacokinetics of the antidiabetic drug, metformin. Metformin 236-245 solute carrier family 22 member 2 Homo sapiens 120-124 19483665-1 2009 OBJECTIVE: The goal of this study was to determine the effect of a genetic variant in the organic cation transporter 2 (OCT2), OCT2-808G/T, which results in an amino acid change, A270S, on the pharmacokinetics of the antidiabetic drug, metformin. Metformin 236-245 solute carrier family 22 member 2 Homo sapiens 127-131 19483665-7 2009 RESULTS: We observed that in HEK-293 stably transfected cells, OCT2-808T had a greater capacity to transport metformin than did the reference OCT2. Metformin 109-118 solute carrier family 22 member 2 Homo sapiens 63-67 19483665-10 2009 Multivariate analysis revealed that OCT2 genotype was a significant predictor of CL(R) and SrCL(R) of metformin (P<0.01). Metformin 102-111 solute carrier family 22 member 2 Homo sapiens 36-40 19483665-11 2009 CONCLUSION: We conclude that genetic variation in OCT2 plays an important role in the CL(R) and SrCL(R) of metformin in healthy volunteers. Metformin 107-116 solute carrier family 22 member 2 Homo sapiens 50-54 19251820-10 2009 Moreover, out of a set of 27 compounds p.270Ala>Ser OCT2 was significantly less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2 (e.g., for propranolol: IC(50) wild type versus p.270Ala>Ser 189 versus 895 microM, P < 0.001). Metformin 131-140 solute carrier family 22 member 2 Homo sapiens 196-200 15783073-0 2005 Metformin transport by renal basolateral organic cation transporter hOCT2. Metformin 0-9 solute carrier family 22 member 2 Homo sapiens 68-73 18401339-0 2008 Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Metformin 82-91 solute carrier family 22 member 2 Homo sapiens 24-52 18401339-1 2008 Genetic variants of the organic cation transporter 2 (protein, OCT2; gene, SLC22A2) were evaluated for their contribution to the variations in the pharmacokinetics of metformin, especially to its renal elimination. Metformin 167-176 solute carrier family 22 member 2 Homo sapiens 24-52 18401339-1 2008 Genetic variants of the organic cation transporter 2 (protein, OCT2; gene, SLC22A2) were evaluated for their contribution to the variations in the pharmacokinetics of metformin, especially to its renal elimination. Metformin 167-176 solute carrier family 22 member 2 Homo sapiens 63-67 18401339-1 2008 Genetic variants of the organic cation transporter 2 (protein, OCT2; gene, SLC22A2) were evaluated for their contribution to the variations in the pharmacokinetics of metformin, especially to its renal elimination. Metformin 167-176 solute carrier family 22 member 2 Homo sapiens 75-82 18551044-0 2008 OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Metformin 74-83 solute carrier family 22 member 2 Homo sapiens 0-4 18551044-8 2008 CONCLUSION: Our study results demonstrated for the first time the existence of genetic polymorphisms of OCT2 in the Chinese population, and further showed that the 808G>T polymorphism is associated with a reduced metformin renal or tubular clearance. Metformin 216-225 solute carrier family 22 member 2 Homo sapiens 104-108 18303133-17 2008 Drugs that interfere with elimination-that is, other drugs utilizing the organic cation transporter-2 in the tubule, such as trimethoprim, metformin, or imipramine-may lead to drug accumulation. Metformin 139-148 solute carrier family 22 member 2 Homo sapiens 73-101 15783073-2 2005 This study was performed to characterize metformin transport by human organic cation transporter 2 (hOCT2), the most abundant organic cation transporter in the basolateral membranes of the human kidney. Metformin 41-50 solute carrier family 22 member 2 Homo sapiens 70-98 15783073-2 2005 This study was performed to characterize metformin transport by human organic cation transporter 2 (hOCT2), the most abundant organic cation transporter in the basolateral membranes of the human kidney. Metformin 41-50 solute carrier family 22 member 2 Homo sapiens 100-105 15783073-3 2005 METHODS: Accumulation of [14C]metformin was assessed by the tracer experiments in the human embryonic kidney (HEK293) cells expressing hOCT2. Metformin 30-39 solute carrier family 22 member 2 Homo sapiens 135-140 15783073-4 2005 RESULTS: The transport of [14C]metformin was markedly stimulated in hOCT2-expressing cells compared with the vector-transfected cells. Metformin 31-40 solute carrier family 22 member 2 Homo sapiens 68-73 15783073-6 2005 The apparent Km and Vmax values of [14C]metformin transport by hOCT2-expressing HEK293 cells were 1.38+/-0.21 mM and 11.9+/-1.5 nmol mg protein(-1) min(-1), respectively. Metformin 40-49 solute carrier family 22 member 2 Homo sapiens 63-68 15783073-7 2005 The order of the potencies of unlabeled biguanides to inhibit [14C]metformin transport by hOCT2 was phenformin > buformin > metformin. Metformin 67-76 solute carrier family 22 member 2 Homo sapiens 90-95 15783073-7 2005 The order of the potencies of unlabeled biguanides to inhibit [14C]metformin transport by hOCT2 was phenformin > buformin > metformin. Metformin 130-139 solute carrier family 22 member 2 Homo sapiens 90-95 15783073-9 2005 CONCLUSIONS: Metformin is transported by the basolateral organic cation transporter hOCT2 in the human kidney. Metformin 13-22 solute carrier family 22 member 2 Homo sapiens 84-89 15783073-10 2005 hOCT2 could play a role in the drug interactions between metformin and some cationic drugs. Metformin 57-66 solute carrier family 22 member 2 Homo sapiens 0-5 34502566-6 2021 ASP+ uptake was inhibited by tetraethylammonium (TEA+), tetrapentylammonium (TPA+), metformin and baricitinib both in the hOCT2-HEK cells and the hOCT2- MDCK cysts, even though the apparent affinities of TEA+ and baricitinib were dependent on the expression system. Metformin 84-93 solute carrier family 22 member 2 Homo sapiens 122-127 34884730-5 2021 By contrast, only 4/15 substrates, i.e., acetylcholine, agmatine, choline and metformin, trans-stimulated DiASP uptake, with a full suppression of the trans-stimulating effect of metformin by the reference OCT2 inhibitor amitriptyline. Metformin 179-188 solute carrier family 22 member 2 Homo sapiens 206-210 35147740-5 2022 The validated model was used to simulate DDIs of dasatinib and known substrates for OCT2 and MATEs (metformin) and OATP1B1/1B3 (pravastatin and rosuvastatin). Metformin 100-109 solute carrier family 22 member 2 Homo sapiens 84-88 34064886-2 2021 Hepatic OCT1, intestinal OCT3, renal OCT2 on tubule basolateral membrane, and MATE1/2-K on tubule apical membrane coordinately work to control metformin disposition. Metformin 143-152 solute carrier family 22 member 2 Homo sapiens 37-41 34064886-7 2021 Individual contributions of transporters to metformin disposition are renal OCT2 renal MATEs > intestinal OCT3 > hepatic OCT1 > intestinal PMAT. Metformin 44-53 solute carrier family 22 member 2 Homo sapiens 76-80 35183887-11 2022 Altogether, our data suggest that tamsulosin could increase systemic exposure and reduce excretion of metformin via inhibiting Oct2 and Mate1-mediated transport cooperatively. Metformin 102-111 solute carrier family 22 member 2 Homo sapiens 127-131 35147740-7 2022 Sensitivity analysis showed metformin exposure increased < 30% in both AUC and Cmax when dasatinib Ki was reduced by tenfold for OCT2 and MATEs simultaneously, and < 40% with a 20-fold Ki reduction. Metformin 28-37 solute carrier family 22 member 2 Homo sapiens 129-133 32989831-4 2021 In vitro, tucatinib inhibited OCT2-, MATE1-, and MATE2-K-mediated transport of metformin, with IC50 values of 14.7, 0.340, and 0.135 microM, respectively. Metformin 79-88 solute carrier family 22 member 2 Homo sapiens 30-34 35163393-7 2022 Dividing these values into the different Jmax values for transport of MPP, metformin, and atenolol mediated by MATE1 and OCT2 resulted in calculated TOR values (+-SE, n = 4) of 84.0 +- 22.0 s-1 and 2.9 +- 0.6 s-1; metformin, 461.0 +- 121.0 s-1 and 12.6 +- 2.4 s-1; atenolol, 118.0 +- 31.0 s-1, respectively. Metformin 75-84 solute carrier family 22 member 2 Homo sapiens 121-125 35163393-7 2022 Dividing these values into the different Jmax values for transport of MPP, metformin, and atenolol mediated by MATE1 and OCT2 resulted in calculated TOR values (+-SE, n = 4) of 84.0 +- 22.0 s-1 and 2.9 +- 0.6 s-1; metformin, 461.0 +- 121.0 s-1 and 12.6 +- 2.4 s-1; atenolol, 118.0 +- 31.0 s-1, respectively. Metformin 214-223 solute carrier family 22 member 2 Homo sapiens 121-125 31936070-12 2020 Thus, these findings suggest that MLE lowered the elimination of Met via inhibiting the hOCT2. Metformin 65-68 solute carrier family 22 member 2 Homo sapiens 88-93 32472157-3 2020 Hepatic and renal uptake of metformin is mediated by organic cation transporter 1 (OCT1) and OCT2, respectively, and its renal excretion by multidrug and toxin extrusion 1 (MATE1) and MATE2-K. Metformin 28-37 solute carrier family 22 member 2 Homo sapiens 93-97 32455555-7 2020 In our results, verapamil inhibited the OCT2-mediated renal excretion of metformin, subsequently leading to increase of the systemic exposure of metformin. Metformin 73-82 solute carrier family 22 member 2 Homo sapiens 40-44 32455555-7 2020 In our results, verapamil inhibited the OCT2-mediated renal excretion of metformin, subsequently leading to increase of the systemic exposure of metformin. Metformin 145-154 solute carrier family 22 member 2 Homo sapiens 40-44 32455555-9 2020 Although the further clinical investigation is required, our finding suggests a possibility of OCT2-mediated interaction of metformin and verapamil. Metformin 124-133 solute carrier family 22 member 2 Homo sapiens 95-99 32449077-4 2020 OBJECTIVE: The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug-gene interaction, the cimetidine-metformin drug-drug interaction, and the impact of renal impairment on metformin exposure. Metformin 125-134 solute carrier family 22 member 2 Homo sapiens 197-204 32449077-4 2020 OBJECTIVE: The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug-gene interaction, the cimetidine-metformin drug-drug interaction, and the impact of renal impairment on metformin exposure. Metformin 187-196 solute carrier family 22 member 2 Homo sapiens 197-204 32449077-4 2020 OBJECTIVE: The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug-gene interaction, the cimetidine-metformin drug-drug interaction, and the impact of renal impairment on metformin exposure. Metformin 187-196 solute carrier family 22 member 2 Homo sapiens 197-204 32449077-4 2020 OBJECTIVE: The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug-gene interaction, the cimetidine-metformin drug-drug interaction, and the impact of renal impairment on metformin exposure. Metformin 187-196 solute carrier family 22 member 2 Homo sapiens 197-204 31012983-1 2019 The organic cation transporters OCT1 and OCT2 and the multidrug and toxin extrusion transporter MATE1, encoded by the SLC22A1, SLC22A2, and SLC47A1 genes, respectively, are responsible for the absorption of metformin in enterocytes, hepatocytes, and kidney cells. Metformin 207-216 solute carrier family 22 member 2 Homo sapiens 41-45 31012983-1 2019 The organic cation transporters OCT1 and OCT2 and the multidrug and toxin extrusion transporter MATE1, encoded by the SLC22A1, SLC22A2, and SLC47A1 genes, respectively, are responsible for the absorption of metformin in enterocytes, hepatocytes, and kidney cells. Metformin 207-216 solute carrier family 22 member 2 Homo sapiens 127-134 31012983-2 2019 The aim of this study was to evaluate whether genetic variations in the SLC22A1, SLC22A2, and SLC47A1 genes could be associated with an altered response to metformin in patients with type 2 diabetes mellitus. Metformin 156-165 solute carrier family 22 member 2 Homo sapiens 81-88 30934600-0 2019 Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels. Metformin 0-9 solute carrier family 22 member 2 Homo sapiens 48-55 30959948-4 2019 In this study, we investigated the association between the polymorphisms of OCT1 and OCT2 and the treatment effectiveness of metformin in PCOS patients. Metformin 125-134 solute carrier family 22 member 2 Homo sapiens 85-89 30934600-3 2019 The objective of this study was to investigate the relationship between twenty-one single nucleotide polymorphisms (SNPs) in the SLC22A1, SLC22A2, and SLC22A3 genes and their effects on metformin pharmacogenetics in Jordanian patients diagnosed with type 2 diabetes mellitus. Metformin 186-195 solute carrier family 22 member 2 Homo sapiens 138-145 30804576-1 2019 OBJECTIVE: To determine the frequencies of single nucleotide polymorphisms rs201919874 and rs138244461 in genes SLC22A2 and SLC47A2 respectively in Pakistani diabetes patients in order to characterise the genetic variants and determine their association with the pharmacokinetics of metformin. Metformin 283-292 solute carrier family 22 member 2 Homo sapiens 112-119 30733798-9 2018 In this study, we used computational approaches to investigate the effect of 270A > S change in SLC22A2 on interaction with metformin and other drugs. Metformin 127-136 solute carrier family 22 member 2 Homo sapiens 99-106 30733798-0 2018 Interaction of rs316019 variants of SLC22A2 with metformin and other drugs- an in silico analysis. Metformin 49-58 solute carrier family 22 member 2 Homo sapiens 36-43 30733798-5 2018 The 270S form of SLC22A2 clears metformin from circulation at much reduced level compared to the 270A form. Metformin 32-41 solute carrier family 22 member 2 Homo sapiens 17-24 28483424-4 2017 We first screened 72 uremic solutes as inhibitors of [14C]-labeled metformin uptake by OCT2. Metformin 67-76 solute carrier family 22 member 2 Homo sapiens 87-91 29914345-5 2018 RESULTS: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. Metformin 123-132 solute carrier family 22 member 2 Homo sapiens 48-55 29914345-7 2018 CONCLUSION: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin. Metformin 122-131 solute carrier family 22 member 2 Homo sapiens 49-56 29490902-3 2018 The objectives of this study were to use a physiologically based pharmacokinetic modeling platform to 1) assess the impact of alterations in DT expression, toxin-drug interactions (TDIs), and free fraction (fu) on PK predictions for the organic cation transporter 2/multidrug and toxin extrusion protein 1 substrate metformin in RI populations; and 2) use available in vitro data to improve predictions of CLR for two actively secreted substrates, metformin and ranitidine. Metformin 316-325 solute carrier family 22 member 2 Homo sapiens 237-305 29490902-3 2018 The objectives of this study were to use a physiologically based pharmacokinetic modeling platform to 1) assess the impact of alterations in DT expression, toxin-drug interactions (TDIs), and free fraction (fu) on PK predictions for the organic cation transporter 2/multidrug and toxin extrusion protein 1 substrate metformin in RI populations; and 2) use available in vitro data to improve predictions of CLR for two actively secreted substrates, metformin and ranitidine. Metformin 448-457 solute carrier family 22 member 2 Homo sapiens 237-305 29204687-9 2018 Specific DDI simulations using PBPK models of simvastatin (OATP1B3 substrate) and metformin (OCT2 substrate) predict no significant changes of the plasma concentrations of these two victim drugs during co-administration. Metformin 82-91 solute carrier family 22 member 2 Homo sapiens 93-97 26784938-1 2016 PURPOSE: Human multidrug and toxin extrusion member 1 (MATE1, SLC47A1) and Organic Cation Transporter 2 (OCT2, SLC22A2) play important roles in the renal elimination of various pharmacologic agents, including the anti-diabetic drug metformin. Metformin 232-241 solute carrier family 22 member 2 Homo sapiens 75-103 28069720-2 2017 As pregnancy increased the renal secretion of metformin, a substrate for OCT2, MATE1, and MATE2-K, we hypothesized that the renal secretion of 1-NMN would be similarly affected. Metformin 46-55 solute carrier family 22 member 2 Homo sapiens 73-77 28253084-2 2017 Many pharmacologically significant compounds are transported by SLC22A2, including the antidiabetic drug metformin, anticancer agent cisplatin, and antiretroviral lamivudine. Metformin 105-114 solute carrier family 22 member 2 Homo sapiens 64-71 27555891-7 2016 Inter-individual variability in response to OADs is due to polymorphisms in genes encoding drug receptors, transporters, and metabolizing enzymes for example, genetic variants in solute carrier transporters (SLC22A1, SLC22A2, SLC22A3, SLC47A1 and SLC47A2) are actively involved in glycemic/HbA1c management of metformin. Metformin 310-319 solute carrier family 22 member 2 Homo sapiens 217-224 26974526-2 2016 This study assessed the effect of dolutegravir on the pharmacokinetics of metformin, an OCT2 substrate. Metformin 74-83 solute carrier family 22 member 2 Homo sapiens 88-92 26974526-12 2016 CONCLUSIONS: Dolutegravir significantly increased metformin plasma exposure, which can be partially explained by OCT2 inhibition. Metformin 50-59 solute carrier family 22 member 2 Homo sapiens 113-117 27828777-3 2016 Additionally, further studies have reported that SLC22A2 is responsible for 80% of the total metformin clearance. Metformin 93-102 solute carrier family 22 member 2 Homo sapiens 49-56 27828777-4 2016 Therefore, loss-of-function variants of SLC22A2 could affect the pharmacokinetic and pharmacodynamic characteristics of metformin. Metformin 120-129 solute carrier family 22 member 2 Homo sapiens 40-47 27609360-0 2016 Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients. Metformin 65-74 solute carrier family 22 member 2 Homo sapiens 87-91 27609360-9 2016 CONCLUSIONS: For the first time, we have identified an association between the lack of metformin response and SNPs rs3119309 and rs7757336 located in the 5" flanking region of the genes coding for Organic cation transporter 2 and rs2481030 located in the 5" flanking region of Organic cation transporter 3 that was supported by the results of a pharmacokinetic study on 25 healthy volunteers. Metformin 87-96 solute carrier family 22 member 2 Homo sapiens 197-225 26784938-1 2016 PURPOSE: Human multidrug and toxin extrusion member 1 (MATE1, SLC47A1) and Organic Cation Transporter 2 (OCT2, SLC22A2) play important roles in the renal elimination of various pharmacologic agents, including the anti-diabetic drug metformin. Metformin 232-241 solute carrier family 22 member 2 Homo sapiens 105-109 26784938-1 2016 PURPOSE: Human multidrug and toxin extrusion member 1 (MATE1, SLC47A1) and Organic Cation Transporter 2 (OCT2, SLC22A2) play important roles in the renal elimination of various pharmacologic agents, including the anti-diabetic drug metformin. Metformin 232-241 solute carrier family 22 member 2 Homo sapiens 111-118 26784938-2 2016 The goal of this study was to determine the association between metformin"s pharmacokinetics and pharmacodynamics and the genetic variants of MATE1 (rs2289669) and OCT2 (rs316019) before and after treatment with the potential MATE inhibitor, ranitidine. Metformin 64-73 solute carrier family 22 member 2 Homo sapiens 164-168 25527093-9 2015 The addition of metformin or cimetidine significantly reduced the creatinine transepithelial flux, indicating active creatinine uptake in ciPTECs, most likely mediated by the organic cation transporter, OCT2 (SLC22A2). Metformin 16-25 solute carrier family 22 member 2 Homo sapiens 203-207 25662675-0 2015 The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin. Metformin 144-153 solute carrier family 22 member 2 Homo sapiens 12-40 25662675-0 2015 The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin. Metformin 144-153 solute carrier family 22 member 2 Homo sapiens 42-46 25662675-2 2015 Organic cation transporter 2 (OCT2) is responsible for 80% metformin clearance. Metformin 59-68 solute carrier family 22 member 2 Homo sapiens 0-28 25662675-2 2015 Organic cation transporter 2 (OCT2) is responsible for 80% metformin clearance. Metformin 59-68 solute carrier family 22 member 2 Homo sapiens 30-34 25662675-4 2015 In this study, we examined the role of OCT2-T201M (602 C>T) variant in insulin resistance in patients with type 2 diabetes (T2D) who were treated with metformin. Metformin 154-163 solute carrier family 22 member 2 Homo sapiens 39-43 25662675-11 2015 CONCLUSIONS: Our findings suggest that the loss-of-function variant OCT2-T201M (rs145450955) contribute to changes in insulin resistance and beta cell activity in patients with T2D treated with metformin. Metformin 194-203 solute carrier family 22 member 2 Homo sapiens 68-72 25527093-9 2015 The addition of metformin or cimetidine significantly reduced the creatinine transepithelial flux, indicating active creatinine uptake in ciPTECs, most likely mediated by the organic cation transporter, OCT2 (SLC22A2). Metformin 16-25 solute carrier family 22 member 2 Homo sapiens 209-216 25125398-1 2014 A high throughput LC-MS/MS method for quantification of metformin substrate uptake enables conversion of radiometric transporter inhibition assays for multidrug and toxin extrusion transporters (MATE 1 and 2) and organic cation transporter 2 (OCT2) to a nonradioactive format. Metformin 56-65 solute carrier family 22 member 2 Homo sapiens 213-241 25573751-0 2015 Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. Metformin 81-90 solute carrier family 22 member 2 Homo sapiens 16-44 25573751-1 2015 BACKGROUND AND OBJECTIVES: This study aimed to investigate how the organic cation transporter 2 nucleotide polymorphism at site 808 (G T) affects metformin pharmacokinetics and its long-term anti-diabetic effect. Metformin 148-157 solute carrier family 22 member 2 Homo sapiens 67-95 25573751-8 2015 CONCLUSION: As well as gender, the glucose-lowering efficiency of metformin can be enhanced by SLC22A2 808G > T variants through the delay of its transportation and CLr in Chinese type 2 diabetes populations. Metformin 66-75 solute carrier family 22 member 2 Homo sapiens 95-102 25359200-5 2015 In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 muM, respectively. Metformin 61-70 solute carrier family 22 member 2 Homo sapiens 47-51 25394090-3 2014 In vitro, DTG inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE 1) which are known to be involved in the disposition of metformin. Metformin 169-178 solute carrier family 22 member 2 Homo sapiens 23-51 25394090-3 2014 In vitro, DTG inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE 1) which are known to be involved in the disposition of metformin. Metformin 169-178 solute carrier family 22 member 2 Homo sapiens 53-57 25125398-1 2014 A high throughput LC-MS/MS method for quantification of metformin substrate uptake enables conversion of radiometric transporter inhibition assays for multidrug and toxin extrusion transporters (MATE 1 and 2) and organic cation transporter 2 (OCT2) to a nonradioactive format. Metformin 56-65 solute carrier family 22 member 2 Homo sapiens 243-247 24026623-2 2013 Although no inhibition of OAT1 and OAT3 was observed, inhibition of OCT2-mediated uptake of 1-methyl-4-phenylpyridinium (MPP(+)) and metformin was evident (IC(50) of 73.4 +- 14.8 and 8.8 +- 1.9 microM, respectively). Metformin 133-142 solute carrier family 22 member 2 Homo sapiens 68-72 24657329-7 2014 All of the nine antidepressant compounds showed moderate inhibitory effects on OCT2-mediated metformin, serotonin and/or norepinephrine uptake. Metformin 93-102 solute carrier family 22 member 2 Homo sapiens 79-83 24001450-4 2013 The inhibitory potencies of ondansetron on metformin accumulation mediated by OCT2 and MATEs were determined in the stable HEK-293 cells expressing these transporters. Metformin 43-52 solute carrier family 22 member 2 Homo sapiens 78-82 23305245-2 2013 The aim of this study was to investigate the effects of trimethoprim on metformin pharmacokinetics and genetic modulation by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion 1 (MATE1) polymorphisms. Metformin 72-81 solute carrier family 22 member 2 Homo sapiens 155-159 23582785-4 2013 Metformin has been reported to be mainly excreted into urine by human organic cation transporter 2 (hOCT2). Metformin 0-9 solute carrier family 22 member 2 Homo sapiens 70-98 23852330-7 2013 The pivotal role of hOCT2 for renal secretion of creatinine and metformin was confirmed in clinical studies. Metformin 64-73 solute carrier family 22 member 2 Homo sapiens 20-25 23709117-5 2013 Here we compared the IC50 values obtained for a set of structurally distinct inhibitors against OCT2-mediated transport of three structurally distinct substrates: 1-methyl-4-phenylpyridinium (MPP); metformin; and a novel fluorescent substrate, N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][l,2,5]oxadiazol-4-yl)amino]ethanaminium iodide (NBD-MTMA). Metformin 198-207 solute carrier family 22 member 2 Homo sapiens 96-100 23582785-4 2013 Metformin has been reported to be mainly excreted into urine by human organic cation transporter 2 (hOCT2). Metformin 0-9 solute carrier family 22 member 2 Homo sapiens 100-105 23582785-10 2013 The results suggest that plasma concentration of phenformin in subjects carrying hOCT2 variant may be higher compared to reference subjects, as reported in metformin. Metformin 156-165 solute carrier family 22 member 2 Homo sapiens 81-86 22861817-3 2013 As organic cation transporters (OCT) belonging to the solute carrier 22A gene family, including OCT-1, OCT-2, and OCT-3, mediate metformin uptake and activity, it is critical to define what role they play in the antineoplastic activity of metformin. Metformin 129-138 solute carrier family 22 member 2 Homo sapiens 103-108 22735389-0 2012 Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Metformin 197-206 solute carrier family 22 member 2 Homo sapiens 74-78 22735389-2 2012 So far, the number of polymorphisms in SLC22A1, SLC22A2, and SLC47A1 genes coding for organic cation transporter 1 (OCT1), OCT2, and multidrug and toxin extrusion transporter 1 (MATE1) metformin transporters have been described in association with the efficacy of metformin. Metformin 185-194 solute carrier family 22 member 2 Homo sapiens 48-55 22735389-2 2012 So far, the number of polymorphisms in SLC22A1, SLC22A2, and SLC47A1 genes coding for organic cation transporter 1 (OCT1), OCT2, and multidrug and toxin extrusion transporter 1 (MATE1) metformin transporters have been described in association with the efficacy of metformin. Metformin 185-194 solute carrier family 22 member 2 Homo sapiens 123-127